Can I Take N-Acetylcysteine (NAC) with Losartan?

Losartan (brand name Cozaar) is an angiotensin II receptor blocker (ARB) approved by the FDA to treat high blood pressure, slow the progression of diabetic kidney disease, and lower stroke risk in people with high blood pressure and heart enlargement. N-acetylcysteine (NAC) is derived from the amino acid cysteine and available both as an over-the-counter dietary supplement and as an intravenous medication used in hospital settings for acetaminophen poisoning. When people inquire about using NAC alongside losartan or other blood pressure medications, they are typically referring to the oral supplement version.

The direct answer

Combining oral NAC with losartan is not known to cause a pharmacokinetic drug interaction, and no case series of serious harm from this specific combination appears in the sources reviewed for this page. The plausible concern is additive blood pressure lowering, since losartan blocks the angiotensin II AT1 receptor while NAC's antioxidant activity may support endothelial nitric oxide signaling through a separate pathway. Whether this produces a clinically meaningful drop in blood pressure in a given patient depends on baseline blood pressure, kidney function, and how many other antihypertensive drugs are already on board, factors a prescriber or pharmacist should review before you start, rather than something this page can determine for you.

How each drug affects blood pressure, and why the mechanisms differ

Losartan works by blocking the AT1 receptor, which stops angiotensin II from triggering blood vessel constriction and aldosterone secretion. This receptor-based mechanism is thoroughly established and documented in pharmacology studies of angiotensin II receptor blockers.

NAC's proposed blood pressure effect works through a different route. As a precursor to glutathione, NAC can support the body's antioxidant capacity, and reactive oxygen species are known to degrade nitric oxide in blood vessel walls. Mechanistic and animal work on oxidative stress in hypertension, including studies of NADPH oxidase activity in hypertensive kidney tissue, supports the biological plausibility that reducing oxidative stress could help preserve nitric oxide-mediated vasodilation. [2] This is an argument from mechanism, not a demonstrated blood pressure effect measured in patients taking losartan specifically. A precise average blood pressure change attributable to oral NAC in hypertensive humans, of the kind sometimes quoted online, was not confirmed against a matching primary trial for this article and should be treated as unverified until a specific source is checked.

Because the two mechanisms are pharmacologically distinct, a pharmacodynamic (effect-additive) interaction is plausible in principle even without any pharmacokinetic interaction.

Pharmacokinetics: why no drug-metabolism interaction is expected

Losartan is a prodrug converted mainly by CYP2C9 (with a minor CYP3A4 contribution) to its active metabolite, EXP3174, which does the bulk of the AT1-blocking work. [3] NAC is not established as a clinically meaningful inhibitor or inducer of CYP2C9 or CYP3A4 at typical oral supplement doses, so losartan and EXP3174 plasma levels are not expected to change when NAC is added.

Oral NAC itself has low and variable bioavailability, generally in the single-digit to low-double-digit percentage range, because of extensive first-pass metabolism after absorption. [4] Both compounds are cleared partly through the kidney, which is the main reason kidney function matters for this combination (see below) rather than any drug-metabolism competition between them.

Who should be most careful about starting NAC while on losartan

Older adults and anyone prone to orthostatic hypotension. Baroreceptor reflex sensitivity and vascular compliance both decline with age. Reviews of orthostatic hypotension in older adults describe it as common in this population, though the exact prevalence cited varies by study population and definition used. [9] A patient whose systolic blood pressure already runs low to normal on losartan has less room to absorb any additional blood-pressure-lowering effect without symptoms.

People with CKD stage 3 or higher. Both losartan and NAC undergo renal clearance, and blood pressure targets are tighter in chronic kidney disease. The KDIGO 2021 guideline recommends a systolic blood pressure target below 120 mmHg for most adults with CKD, measured under standardized conditions. [10] Because this target is already low, additive blood pressure lowering from a supplement is worth monitoring rather than assuming will be harmless.

People taking more than one antihypertensive drug. Adding NAC to a regimen that already includes losartan plus a calcium-channel blocker or diuretic introduces another variable into an already-stacked blood-pressure-lowering effect. This is not a contraindication, but it is a reason to track blood pressure rather than start and forget.

Does NAC offer a specific benefit for people on losartan?

Losartan's approved indication for diabetic nephropathy is supported by the RENAAL trial, which found that losartan reduced the risk of doubling serum creatinine over roughly 3.4 years of follow-up compared with placebo in patients with type 2 diabetes and nephropathy. [8] Oxidative stress is an independent contributor to glomerular injury in diabetic kidney disease, which is the mechanistic reason some researchers have proposed antioxidant support, including NAC, as a complementary strategy alongside ARB therapy. This idea has biological plausibility, but a large trial directly testing losartan plus NAC against losartan alone for a hard renal endpoint was not identified in the sources for this page, and claims of a specific human combination trial should not be treated as established without checking the primary literature first.

Losartan is not FDA-approved for heart failure with reduced ejection fraction; ARBs with that indication include other agents in the class. Some clinicians use losartan off-label in heart failure patients who cannot tolerate an ACE inhibitor, and NAC is separately used as a mucolytic in patients with chronic respiratory disease, including COPD, where a placebo-controlled trial found fewer exacerbations with NAC over three years. [11] These are two legitimate but separate uses that can overlap in the same patient; neither establishes a losartan-specific interaction beyond the general blood-pressure caution described above.

NAC is also used off-label for polycystic ovary syndrome (PCOS), where some small trials have reported improved ovulation rates compared with placebo when combined with clomiphene in women with clomiphene-resistant PCOS, though this claim could not be matched to a verified source here. Some women with PCOS also have hypertension or cardiometabolic risk factors and may already be on losartan, which is one reason the same monitoring principle (check blood pressure after adding NAC) applies here too.

What this evidence base does and does not establish

Established: Losartan's mechanism of action, its FDA-approved indications, and its metabolism through CYP2C9 are well documented. [1][3] NAC's low oral bioavailability and general safety profile at supplement doses are also well documented. [4] No confirmed pharmacokinetic interaction between the two exists in the literature reviewed here.

Plausible but unproven: That NAC produces a clinically meaningful additive blood-pressure-lowering effect specifically in patients already taking losartan. The mechanism is reasonable (two different pathways converging on vascular tone), but a dedicated trial measuring blood pressure in losartan-treated patients before and after adding NAC was not located for this page.

Not established: That combining losartan with NAC produces superior renal protection or any other clinical outcome compared with losartan alone in humans. Mechanistic and animal-adjacent reasoning supports the idea; a confirmatory human outcomes trial does not appear to exist yet in the sources checked.

Evidence-status table: what is known, what is assumed, and what to verify

Practical monitoring if you start both

Check blood pressure at baseline, then again roughly two to four weeks after adding NAC, using a validated home cuff if possible. If systolic pressure falls below about 100 mmHg, or you notice dizziness on standing, unusual fatigue, or blurred vision, stop the NAC and contact your prescriber rather than waiting for a scheduled visit.

If you have CKD or diabetes, ask whether a follow-up check of kidney function and potassium makes sense a few weeks after starting NAC, since losartan already affects potassium handling through its effect on aldosterone, and confirming stability after any medication change is reasonable practice.

There is no pharmacokinetic reason to separate the timing of NAC and losartan doses. Losartan is typically taken once daily; NAC is often better tolerated with food. A common approach is taking NAC with a meal and losartan at a consistent time each day, but this is a tolerability choice, not a requirement based on drug interaction data.

When to seek urgent care

Symptoms such as fainting, chest pain, severe dizziness, or confusion after starting a new supplement are not routine monitoring issues and warrant urgent medical evaluation rather than waiting for a scheduled follow-up.

What to tell your prescriber

Before starting NAC, tell your prescriber the dose you plan to take, why you are taking it, and your most recent home blood pressure readings. The FDA's general guidance on supplements recommends disclosing all supplement use at every prescribing encounter, precisely because interactions like the one described here are easy to miss if a clinician does not know a supplement is being used. [12]